相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
Rom Leidner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).
Trisha Michel Wise-Draper et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Robert L. Ferris et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Jose Carlos Benitez et al.
CLINICAL CANCER RESEARCH (2020)
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri et al.
CLINICAL CANCER RESEARCH (2020)
Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer
R. Zinner et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
L. Zuur et al.
ANNALS OF ONCOLOGY (2020)
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma
Henrike B. Zech et al.
FUTURE ONCOLOGY (2020)
Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
Hui-Ching Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
Jonathan D. Schoenfeld et al.
JAMA ONCOLOGY (2020)
Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials
Gaber Plavc et al.
RADIOLOGY AND ONCOLOGY (2020)
Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment
Susanne Wiegand et al.
FRONTIERS IN ONCOLOGY (2019)
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Joshua Dean Horton et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.
Renata Ferrarotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
M. Oliva et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study
Kai Wang et al.
RADIATION ONCOLOGY (2019)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2018)
Fast Forward - Neoadjuvant Cancer Immunotherapy
Thomas F. Gajewski
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Untitled
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness et al.
ANNALS OF ONCOLOGY (2018)
Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
R. Haddad et al.
ANNALS OF ONCOLOGY (2017)
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma
Glenn J. Hanna et al.
ORAL ONCOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis
Ashley Lau et al.
ORAL ONCOLOGY (2016)
Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Untitled
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis
Gustavo N. Marta et al.
EUROPEAN JOURNAL OF CANCER (2015)
Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial
P. Bossi et al.
ANNALS OF ONCOLOGY (2014)
Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
Rupal Ramakrishnan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
Lai-ping Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
Robert Haddad et al.
LANCET ONCOLOGY (2013)
Influence of pathologic complete response to neoadjuvant chemotherapy on long-term survival of patients with advanced head and neck squamous cell carcinoma
Xin-rui Zhang et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2013)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
Galina V. Shurin et al.
JOURNAL OF IMMUNOLOGY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Primary chemotherapy in resectable oral cavity squamous cell cancer:: A randomized controlled trial
L Licitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
